Skip to main content
BIO
NYSE Life Sciences

Bio-Rad Q3 Revenue Edges Past Estimates as Clinical Diagnostics Offsets Life Science Weakness

Tom Rudovsky · Reported by Reuters
More coverage: Medical Device Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$379.29
Mkt Cap
$10.188B
52W Low
$236.73
52W High
$396.23
52W Position info
60% above low
Off High info
4.3% below high
Rel. Volume info
1.1× avg
Market data snapshot near publication time

BIO sits 60% above its 52-week low of $236.73.

Summary

Q3 revenue came in at $656.40 million versus $649.95 million consensus — a beat of under 1%, so barely a beat. Adjusted EPS rose to $2.65 from $2.26 a year earlier, a real improvement in core profitability. Growth came from Clinical Diagnostics, specifically quality systems and diabetes products, plus higher Droplet Digital PCR demand; that offset declines in Life Science, where process chromatography and academic research spending stayed weak. The reported $458.6 million net income is almost entirely a non-cash mark-to-market gain on the Sartorius stake, not operations — the 8-K filed this afternoon shows core operations lost $49.7 million after restructuring and a Celsee charge. Guidance is the soft spot: 2026 non-GAAP currency-neutral revenue of down 3% to up 0.5%, with operating margin held at 10% to 12%. Stock sits near its 52-week high at roughly 37x forward earnings, so the bar was high and this is a modest pass, not a blowout.

At the time of this announcement, BIO was trading at $379.29 on NYSE in the Life Sciences sector, with a market capitalization of approximately $10.2B. The 52-week trading range was $236.73 to $396.23. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.


Price Chart

Share this article

Copied!

BIO - Latest Insights

BIO
Nov 04, 2026, 4:19 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $379.29
Real-time Price: $367.50 info
Change: -$11.79 (-3%) info
Market Cap: $9.933B info
BIO
Nov 04, 2026, 4:16 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $379.29
Real-time Price: $367.50 info
Change: -$11.79 (-3%) info
Market Cap: $9.933B info
BIO
Aug 04, 2026, 5:42 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $326.33
Real-time Price: $367.50 info
Change: +$41.17 (+13%) info
Market Cap: $9.933B info
BIO
Aug 04, 2026, 4:27 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $326.33
Real-time Price: $367.50 info
Change: +$41.17 (+13%) info
Market Cap: $9.933B info
BIO
Aug 04, 2026, 4:16 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $326.33
Real-time Price: $367.50 info
Change: +$41.17 (+13%) info
Market Cap: $9.933B info